Emerging anticoagulant and thrombolytic drugs

Emerging Drugs

Volumn 6, Issue 1, 2001, Pages 111-135

  Iqbal, O ^a   Aziz, S ^a   Hoppensteadt, D A ^a   Ahmad, S ^a   Walenga, J M ^a   Bakhos, M ^a   Fareed, J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Heparin; Heparinoids; Heparinomimetic; Hirudin; Peptidomimetic; Thrombocytopenia

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [3 (AMINOIMINOMETHYL)PHENYL] 5 [(2' AMINOSULFONYL 1,1' BIPHENYL 4 YL)CARBAMOYL] 4,5 DIHYDRO 5 ISOXAZOLEACETIC ACID METHYL ESTER; 3 [3 (AMINOIMINOMETHYL)PHENYL] N (2' AMINOSULFONYL 1,1' BIPHENYL 4 YL) 4,5 DIHYDRO 5 (1H TETRAZOL 1 YLMETHYL) 5 ISOXAZOLECARBOXAMIDE; ANCROD; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CGP 16056; CVS 995; CX 397; DALTEPARIN; DANAPAROID; DERMATAN SULFATE; DESMIN; EFEGATRAN; ENOXAPARIN; GM 1630; GS 522; HC 977; HEPARIN; HEPARINOID; HIRUDIN; HIRULOG; HV 1; INOGATRAN; INTIMAN; LEX 026; LOW MOLECULAR WEIGHT HEPARIN; LY 293435; MB 015; MELAGATRAN; NADROPARIN; NAPSAGATRAN; OP 435; PENTOSAN POLYSULFATE; PI 88; RECOMBINANT THROMBOMODULIN; SDZ MTH 958; SYNTHETIC PEPTIDE; TENECTEPLASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN INHIBITOR; TIROFIBAN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; XIMELAGATRAN; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID;

ALOPECIA; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FIBRINOLYSIS; HUMAN; NONHUMAN; OSTEOPOROSIS; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 0035027228     PISSN: 13619195     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.6.1.111     Document Type: Review

References (147)

1. Phlogose and thrombose in gefass-system
2. Thrombosis and fibrinolysis
3. The pathogenesis of coronary artery disease and acute coronary syndrome
4. Molecular and cellular biology of blood coagulation
5. Tissue factor dependent autoactivation of human blood coagulation factor
6. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
7. Selective cellular expression of tissue factor in human tissues
8. Protection of Factor Xa from neutralization by heparin antithrombin complex
9. Properties of Factor Xa binding site on platelets
10. Low molecular weight heparins
11. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl]amino) caprylate: Pharmacological considerations
12. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind controlled study in humans
13. Orally administered heparin for preventing deep vein thrombosis
14. Insight into the mechanism of action of heparin cofactor II
15. Dermatan sulfate for the prevention of post-operative venous thrombosis in patients with cancer
16. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist
17. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin
18. Role of endothelial cell surface heparin-like polysaccharides
19. Pharmacology of sulfomucopolysaccharides in atherosclerotic prevention and treatment
20. An overview of non-heparin glycosaminoglycans as antithrombotic agents
21. Heparan sulfate: Efficacy and safety in patients with chronic venous insufficiency
22. Effectiveness of short-term sulfoxide treatment on peripheral vascular disease clinical manifestations
23. Thromboprophylaxis in patients with hip fractures: A prospective, randomized, comparative study between Org 10172 and dextran 70
24. A controlled clinical experiment 'within subjects' with heparan sulfate in intermittent claudication
25. Dermatan sulfate in hemodialysis
26. Dermatan sulfate in acute leukemia
27. Fibrin monomer protects thrombin from inactivation by heparin: Antithrombin III: Implications for heparin efficacy
28. Clot-bound thrombin is protected from inhibition by thrombin-antithrombin III but is susceptible to inactivation by antithrombin III-dependent inhibitors
29. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors
30. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4
31. Cloning and expression of cDNA coding for the anticoagulant hirudin from blood sucking leech, Hirudo medicinalis
32. Kinetics of inhibition of thrombin by hirudin
33. Hirudins: Antithrombotic anticoagulants
34. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia
35. Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis
36. New treatment options for heparin-induced thrombocytopenia
37. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man
38. Recombinant hirudin as an anticoagulant in open-heart surgery: A case report
39. Prevention of deep vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
40. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement
41. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation: A pilot study
42. Effects of recombinant hirudin (lepirudin) compared with heparin in patients with acute myocardial ischaemia without ST elevation: A randomized trial
43. Successful use of recombinant hirudin for anticoagulation and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing cardiac bypass surgery (abstract). Session XVII: Perfusion/Cardiac Tumors
44. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors on thrombin
45. Thrombin-specific inhibition by and slow cleavage of hirulog-1
46. Anticoagulant activity of hirulog, a direct inhibitor of thrombin
47. Hirulog: A direct thrombin inhibitor for management of acute coronary syndromes
48. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina
49. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for post-infarction angina
50. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction
51. Argatroban: A synthetic thrombin inhibitor of low relative molecular mass
52. Results of Phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia (HIT)
53. A randomized study of argatroban vs. heparin as adjunctive therapy to tissue plasminogen activator in acute myocardial infarction: MINT (Myocardial Infarction with Novastan and tPAO Study
54. Single and repeated oral dosing of H376/95, a prodrug for the direct thrombin inhibitor, melagatran, to young healthy male subjects
55. Pharmacodynamic properties of H376/95, a prodrug of the direct thrombin inhibitor, melagatran, intended for oral use
56. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation and its stable N-methyl derivative
57. The kinetics of reversible tight-binding inhibition
58. Design and synthesis of potent and highly selective thrombin inhibitors
59. Phase I studies on inogatran, a new selective thrombin inhibitor
60. Active-site blocked Factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model
61. Antithrombotic efficacy of a novel murine antihuman Factor IX antibody in rats
62. An inhibitory antiFactor IX-antibody effectively reduces thrombus formation in a rat model of venous thrombosis
63. A monoclonal antibody to Factor IX that inhibits the Factor VIII: Ca potentiation of Factor X activation
64. Biochemical and pharmacological properties of SANORG 34006, a potent and long acting synthetic pentasaccharide
65. Heparin
66. Structural and functional characterization of a tick anticoagulant peptide (TAP): A potent and selective inhibitor of blood coagulation Factor Xa
67. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and aliciting high anti-Factor Xa activity
68. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III
69. Synthesis of heparin fragments. A chemical synthesis of a pentasaccharide
70. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges
71. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-Factor Xa activity
72. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (Pentasaccharide) in rats
73. Heparinase neutralization of low molecular weight heparins
74. Isolation and characterization of antistatin
75. Antistatin, a leech-derived inhibitor of Factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site
76. FXa inhibitor from the saliva of the leech Hirudo medicinalis
77. Reaction pathway for inhibition of blood coagulation Factor Xa by tick anticoagulant peptide
78. Tick anticoagulant peptide: Kinetic analysis of the recombinant inhibitor with blood coagulation Factor Xa
79. DX-9065a, a novel, synthetic, selective and orally active inhibitor of Factor Xa: In vitro and in vivo studies
80. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human Factor Xa
81. Nonpeptide Factor Xa inhibitors. I. Studies with SF303 and SK549, a new antithrombotic
82. Design and synthesis of isoxazoline derivative as Factor Xa inhibitors
83. Molecular and cellular biology of blood coagulation
84. The lipoprotein-associated coagulation inhibitor that inhibits the Factor VII-tissue factor complex also inhibits Factor Xa: Insight into the possible mechanism of action
85. Modulation of endothelium by heparin and related polyelectrolytes
86. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential
87. Tissue factor pathway inhibitor
88. Ancylostoma caninum anticoagulant peptide: A hookworm derived inhibitor of human coagulation Factor Xa
89. Anticoagulant repertoire of hematophagous nematodes
90. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C
91. Thrombomodulin blocks the ability of thrombin to activate platelets
92. The roles of protein C and thrombomodulin in the regulation of blood coagulation
93. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme
94. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor of protein C activation
95. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice
96. Stable expression of a secretable deletion mutation and recombinant human thrombomodulin in mammalian cells
97. Antithrombotic effects of recombinant human soluble thrombomodulin in a rat model of vascular shunt thrombosis
98. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III
99. Antithrombotic effect of recombinant soluble thrombomodulin on disseminated intravascular coagulation
100. A natural anticoagulant pathway. Biochemistry and physiology of proteins C, S, C4b-binding protein and thrombomodulin
101. Protein S and c4b-binding protein. Components involved in the regulation of the protein C anticoagulant system
102. The protein C pathway
103. Transactivated expression of fully γ-carboxylated recombinant human protein C, antithrombotic factor
104. TAFI or plasma procarboxipeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin- thrombomodulin complex
105. On the mechanism of antifibrinolytic activity of plasma carboxypeptidase B
106. Inducible carboxypeptidase activity: A role in clot lysis in vivo
107. A novel approach to arterial thrombolysis
108. The roles of fibrinogen and fibrin in haemostasis and thrombosis
109. Tridegin, a novel peptide inhibitor of Factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro
110. Tridegin, a new peptide inhibitor of Factor XIIIa, from the blood sucking leech, Haementeria ghilianii
111. Destabilase, the novel epsilon-(gamma-Glu)-Lys isopeptidase with thrombolytic activity
112. Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopeptide bonds and help to dissolve blood clots
113. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil
114. Attenuation of the synthesis of plasminogen activator inhibitor Type 1 by niacin: A potential link between lipid lowering and fibrinolysis
115. The acid stabilization of plasminogen activator inhibitor 1 depends on the protonation of a single group that affects loop insertion into β-sheet A
116. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
117. Novel low molecular weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits
118. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
119. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty: The EPIC Investigators
120. Platelet glycoprotein Ii/Iii receptor blockade and low dose heparin during percutaneous coronary revascularization: The EPILOG Investigators
121. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of platelet IIb/IIIa inhibition in Stenting Investigators
122. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein Ii/Iii in unstable angina: Receptor suppression using integrelin therapy
123. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-q-wave myocardial infarction
124. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
125. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A pooled analysis of the large scale oral glycoprotein IIb/IIIa trials
126. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet pre-eminence
127. Platelet and thrombolytic therapy
128. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation
129. A randomized, placebo-controlled crossover trial of ReoPro alone or combined with low-dose plasminogen activator for coronary reperfusion in patients with acute myocardial infarction: Preliminary results
130. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial
131. Prevention of deep vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
132. A comparison of recombinant hirudin with low molecular weight heparin to prevent thromboembolic complications after total hip replacement
133. Thrombolytic drugs in acute myocardial infarction
134. Bleeding complications with glycoprotein Ii/Iii inhibitors
135. The PENTATHLON 2000 Study: Comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery
136. The EPHESUS Study: Comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin (LMWH). The prevention of venous thromboembolism (VTE) after elective hip replacement surgery
137. The PENTHIFRA Study: Comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin (LMWH). The prevention of venous thromboembolism (VTE) after hip fracture surgery
138. The PENTAMAKS Study: Comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin. The prevention of venous thromboembolism (VTE) after elective major knee surgery
139. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
140. New antithrombotic drugs: A perspective
141. Efficacy and safety of recombinant human activated protein C for severe sepsis
142. Role of GATA motifs in tissue factor pathway inhibitor gene expression in malignant cells
143. New anticoagulant drugs
144. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis